Reducing plasma cholesterol is not the end of the quest
| Autor: | Maryam Shabihkhani, Kaveh Navab, Samra Vazirian, Srinivasa T. Reddy, Maryam Haghnegahdar, Mohamad Navab |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
chemistry.chemical_classification
Apolipoprotein E medicine.medical_specialty Very low-density lipoprotein Apolipoprotein B biology Inflammation Amino acid Endocrinology Chylomicron remnant chemistry Internal medicine medicine biology.protein lipids (amino acids peptides and proteins) medicine.symptom Allele Cardiology and Cardiovascular Medicine Receptor |
| Zdroj: | Atherosclerosis. 227:35-36 |
| ISSN: | 0021-9150 |
| DOI: | 10.1016/j.atherosclerosis.2012.12.034 |
| Popis: | Despite the cholesterol lowering beneficial effects of statins, nearly 70% of cardiovascular disease remains unresolved. High density lipoproteins (HDL), apolipoprotein A-I (the major protein component of HDL), and apoA-I mimetic peptides exert antiinflammatory effects but have not been shown to reduce plasma cholesterol levels. Apolipoprotein E (apoE) is a protein component of chylomicron remnants, very low density lipoprotein (VLDL), and HDL. ApoE is ubiquitously expressed and secreted by many tissues in the body including liver, brain, skin, and tissue macrophages [1]. A common well-characterized polymorphism in human apoE gene accounts for the three alleles, e2, e 3a nde4 that are known to confer resistance or susceptibilitytomany diseasesincludingAlzheimer’sdisease[2]and atherosclerosis [3]. ApoE gene encodes for a 299 amino acid protein containing two domains: a receptor-binding domain at the N-ter |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect